TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04762537

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Induction Procedure (SP)
Description: SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Induction Procedure (RP)
Description: RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
Study: NCT05461612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spatial Resynchronization Therapy delivered by the MAX-SRS, external recording and stimulation device
Description: Delivery of algorithmically defined pacing stimuli over a multitude of electrodes placed on the left atrium.
Study: NCT06166186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: A music with a standard volume will be delivered to the patients via headphones from the beginning of anesthesia induction to extubation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no music
Description: Headphones will be applied to the patients but no music will be played from the beginning of anesthesia induction to extubation.
Study: NCT05772260

Intervention type: PROCEDURE
Intervention: Per-oral endoscopic myotomy
Description: Per-oral endoscopic myotomy will be performed under general anesthesia. Per-oral endoscopic myotomy will be performed according to the standard care.~General anesthesia will be conducted according to the standard care in our institution, and standardized as follows.~* Monitoring: ECG, SpO2, noninvasive blood pressure, invasive blood pressure monitoring via radial artery cannulation, advanced hemodynamic monitoring (including cardiac output, cardiac index) uisng EV1000 clinical platform (Edwards Lifesciences, USA), anesthetic depth monitoring by SedLine Sedation monitor (Masimo corporation).~* Anesthetic induction: Target controlled infusion (TCI) of Remifentanil (target 3.0 ng/mL), propofol 2 mg/kg IV, rocuronium 0.8 mg/kg IV~* Anesthetic maintence: sevoflurane 0.9 age corrected MAC and remifentanil TCI (target range 1.0-4.0 ng/mL)

Intervention type: PROCEDURE
Intervention: Per-oral endoscopic myotomy
Description: Per-oral endoscopic myotomy will be performed under general anesthesia. Per-oral endoscopic myotomy will be performed according to the standard care.~General anesthesia will be conducted according to the standard care in our institution, and standardized as follows.~* Monitoring: ECG, SpO2, noninvasive blood pressure, invasive blood pressure monitoring via radial artery cannulation, advanced hemodynamic monitoring (including cardiac output, cardiac index) uisng EV1000 clinical platform (Edwards Lifesciences, USA), anesthetic depth monitoring by SedLine Sedation monitor (Masimo corporation).~* Anesthetic induction: Target controlled infusion (TCI) of Remifentanil (target 3.0 ng/mL), propofol 2 mg/kg IV, rocuronium 0.8 mg/kg IV~* Anesthetic maintence: sevoflurane 0.9 age corrected MAC and remifentanil TCI (target range 1.0-4.0 ng/mL)
Study: NCT06223282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short inter-set rest resistance exercise
Description: Subjects in short inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 60 sec of rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medium inter-set rest
Description: Subjects in medium inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 120 sec of rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: long inter-set rest
Description: Subjects in long inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 180 sec of rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medium inter-set rest with failure
Description: Subjects in long inter-set rest trial performed 3 sets per exercise, repeated to failure with load of 70%-1RM with 120 sec of rest between sets.
Study: NCT05110053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator
Description: Spinal Cord stimulation is a recognized treatment of chronic neuropathic pain. The procedure of implantation is the same in this study. Surgery is done in local anaesthesia. A small electrode is placed in the epidural space corresponding approximately at the Th8-Th10 level.~An impulsegenerator, connected to the electrode, is placed in the subcutaneus fat in the gluteal region.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Cord Stimulator
Description: Spinal Cord stimulation is a recognized treatment of chronic neuropathic pain. The procedure of implantation is the same in this study. Surgery is done in local anaesthesia. A small electrode is placed in the epidural space corresponding approximately at the Th8-Th10 level.~An impulsegenerator, connected to the electrode, is placed in the subcutaneus fat in the gluteal region.
Study: NCT04704232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACD440
Description: Double blind, parallel within subject comparison

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLAC
Description: Double blind, parallel within subject comparison
Study: NCT05482230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in intubation position
Description: The change of intubation mode is accomplished in lateral position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in intubation position
Description: The change of intubation mode is accomplished in lateral position
Study: NCT04595903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopurifier
Description: Hemopurifier treatments will be one four to six hour treatment session daily for up to 4 days
Study: NCT05874973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-controlled adaptative ventilation (TCAV)
Description: Ventilation with TCAV set on the APRV mode on the ventilator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Description: Ventilation with the VCV mode set on the ventilator.
Study: NCT05651295

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Checking the Facts
Description: Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Checking the Facts
Description: Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opposite to Emotion Action
Description: Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opposite to Emotion Action
Description: Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness of Current Emotions
Description: Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness of Current Emotions
Description: Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
Study: NCT05999188

Intervention type: OTHER
Intervention: Observational
Description: No interventions will be given to patients.
Study: NCT04248413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: The blood flow restriction cuff, which is regulated by the FDA under 878.5910 and is registered under number 9681444, is manufactured by Delfi Medical. The cuff will be used as recommended by the manufacturer and Owens Recovery Science, the company who provides certificating of blood flow restriction training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical rehabilitation
Description: Patients diagnosed with non-operative rotator cuff or biceps tendinopathy will undergo physical rehabilitation under the supervision of the same physical therapists who will be performing the BFR therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard physical rehabilitation
Description: Patients diagnosed with non-operative rotator cuff or biceps tendinopathy will undergo physical rehabilitation under the supervision of the same physical therapists who will be performing the BFR therapy.
Study: NCT04788654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex, acetaminophen, and dexamethasone
Description: Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex, acetaminophen, and dexamethasone
Description: Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline irrigation, aspiration of pneumoperitoneum, and low pressure penumoperitoneum
Description: Surgical intervention will be performed. Saline irrigation, aspiration of pneumoperitoneum, and low pressure pneumoperitoneum will be performed.
Study: NCT05743452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBR with CS@Mg
Description: The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
Study: NCT05802719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: The procedure consists of collecting 4 additional tubes of blood (20mL) at each visit for research purposes, in order to perform the immunological assays.~Blood samples at the inclusion, 3 month and 6 month after initiation of anti-TNF therapy
Study: NCT05878223

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock waves
Description: Both group received extracorporeal shock waves therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock waves
Description: Both group received extracorporeal shock waves therapy
Study: NCT05418777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim Sulfamethoxazole
Description: Receipt of suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receipt of suspension with placebo by mouth every 12 hours for 10 days
Study: NCT04933565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORG-129
Description: ORG-129 oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules
Study: NCT02194751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncoquest-L vaccine
Description: Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
Study: NCT05870267

Intervention type: DEVICE
Intervention: Power Knee with bone anchored suspension
Description: Motor powered microprocessor controlled prosthetic knee joint

Intervention type: DEVICE
Intervention: Power Knee with bone anchored suspension
Description: Motor powered microprocessor controlled prosthetic knee joint

Intervention type: DEVICE
Intervention: C-Leg
Description: Passive hydraulic microprocessor controlled prosthetic knee joint
Study: NCT06208722

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Testing a Mobile App to Improve Toothbrushing Skills and Habits in Teens With Autism
Description: Information provided in arm descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing a Mobile App to Improve Toothbrushing Skills and Habits in Teens With Autism
Description: Information provided in arm descriptions.
Study: NCT06043596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeSpace Sexual Health
Description: The overall goal of the program is to prevent adolescent pregnancy and STIs by increasing sexual agency, increasing the use of condoms and contraception, and promoting healthy relationships and healthy life skills among adolescents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SafeSpace General Health
Description: This arm represents the comparison group. SafeSpace General Health will act as the active comparator, while providing youth with lessons, facts, and resources about general health topics.
Study: NCT05870267

Intervention type: DEVICE
Intervention: Rheo Knee XC
Description: Passive magneto-rheologic microprocessor controlled knee joint
Study: NCT05630079

Intervention type: DEVICE
Intervention: Treatment with Metaneb®
Description: Every patient of this group receive 3 daily treatments of 20 minutes each, performed at approximately 4-hour intervals.~Each treatment with MetaNeb system consists of four cycles: : 5 minutes of Continuous Positive Expiratory Pressure (CPEP) for lung re-expansion (Cycle I), 5 minutes of Chest High Frequency Oscillation (CHFO) for secretion clearance (Cycle II), 5 min of CPEP (Cycle III), 5 minutes of CHFO (Cycle IV). Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It's associated with the administration of aerosols with 10 ml of saline solution 0.9% and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.

Intervention type: DEVICE
Intervention: Treatment with IPV®
Description: Each treatment with IPV provides 3 daily treatments of 20 minutes with the high percussion frequency tolerated by the patient. and I/E ratio: 1/1.2. Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It is associated with the administration of aerosols with 10 ml of saline solution 0.9% \[-\] and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.
Study: NCT05461911

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutrison Advanced Cubison
Description: (20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support
Study: NCT04670926

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TruGraf
Description: TruGraf results will be available in real-time and used by the physician in conjunction with other standard of care labs to guide management of immunosuppression as follows:~Patients with a stable serum creatinine and eGFR of \> 45 mL/min who also have a TruGraf TX result at month 3 will have their Mycophenolate Mofetil or Mycophenolate Sodium decreased from a standard dose of 1000 mg twice daily to 500 mg twice daily or 720 mg twice daily to 360 mg twice daily respectively.~Patients with a stable serum creatinine and estimated eGFR of \> 45 mL/min who also have a TruGraf TX result at months 4, 5, and 6 will have their Tacrolimus target trough level decreased to a target between 3 and 6.~Patients with TruGraf not-TX will have no further immunosuppression reduction and continued to be monitored.
Study: NCT05812404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker
Study: NCT05279547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant-load bed-cycling exercise
Description: Patients will actively cycle for a minimum duration of 10 minutes and a maximum duration of 20 minutes without breaks.
Study: NCT05812404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202201
Description: Atorvastatin Calcium Trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202201
Description: Atorvastatin Calcium Trihydrate
Study: NCT05279547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant-load bed-cycling exercise
Description: Patients will actively cycle for a minimum duration of 10 minutes and a maximum duration of 20 minutes without breaks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval bed-cycling exercise
Description: Patients will cycle for the same duration as during constant-load exercise. Interval bed-cycling session will consist of 30 seconds of high intensity exercise alternated by 30 seconds of passive cycling designed so that volume of training will be equal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval bed-cycling exercise
Description: Patients will cycle for the same duration as during constant-load exercise. Interval bed-cycling session will consist of 30 seconds of high intensity exercise alternated by 30 seconds of passive cycling designed so that volume of training will be equal.
Study: NCT05812404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202201
Description: Atorvastatin Calcium Trihydrate
Study: NCT04955756

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mNGS
Description: Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
Study: NCT05733871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: meal replacement product- STANDARD PRODUCT
Description: standard product line contains common ingredients and this type of product already exists on world markets

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement product- INNOVATIVE PRODUCT
Description: innovative product line contains raw materials that are considered better sources of potentially bioactive components
Study: NCT05218785

Intervention type: DRUG
Intervention: Botox
Description: 75 U in medial gastrocbemius head. x 3
Study: NCT04820894

Intervention type: OTHER
Intervention: Electronic Medical Record
Description: Medical records are reviewed

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT05392686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Tirelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor
Description: Fluzopari capsule
Study: NCT04955756

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Description: Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
Study: NCT03586414

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MITOQUINOL MESYLATE then placebo
Description: MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo, then MITOQUINOL MESYLATE
Description: 'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
Study: NCT05000385

Intervention type: OTHER
Intervention: Assesment of masticatory efficiency with optical scanning method
Description: Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.

Intervention type: OTHER
Intervention: Assesment of masticatory efficiency with optical scanning method
Description: Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.

Intervention type: OTHER
Intervention: Assesment of masticatory efficiency with optical scanning method
Description: Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.

Intervention type: OTHER
Intervention: Assesment of masticatory efficiency with optical scanning method
Description: Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.

Intervention type: DIAGNOSTIC_TEST
Intervention: body mass index
Description: as an indication of nutritional status

Intervention type: DIAGNOSTIC_TEST
Intervention: body mass index
Description: as an indication of nutritional status

Intervention type: DIAGNOSTIC_TEST
Intervention: body mass index
Description: as an indication of nutritional status

Intervention type: DIAGNOSTIC_TEST
Intervention: body mass index
Description: as an indication of nutritional status